AUSTIN, Texas, Feb. 6, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focusing on oncology and cardiology, plans to report preliminary results for its fourth quarter and fiscal year 2011 on Thursday, February 23, 2012.
Company management will host a conference call at 4:30 p.m. Eastern time on the same day to discuss results for the periods, which ended December 31, 2011. Select preliminary unaudited results will be issued in a press release prior to the call.
Vermillion's president and chief executive officer, Gail Page, will host the call, followed by a question and answer period.
Date: Thursday, February 23, 2012Time: 4:30 p.m. Eastern time ( 1:30 p.m. Pacific time)Dial-In Number: 1-800-677-8143International: 1-303-223-2680Conference ID#: 21576618The conference call will be broadcast simultaneously here and available for replay via the investor section of the company's Web site at www.vermillion.com. Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860. A replay of the call will be available approximately two hours after the call and until March 8, 2012. Toll-free replay number: 1-800-633-8284International replay number: 1-402-977-9140Replay pin number: 21576618 About VermillionVermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its well-known scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at www.vermillion.com. Investor Relations:Liolios Group, Inc. Ron BothTel 949-574-3860 Email Contact SOURCE Vermillion, Inc.